Page last updated: 2024-10-27

fluorouracil and Deep Vein Thrombosis

fluorouracil has been researched along with Deep Vein Thrombosis in 63 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)."9.17Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013)
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches."9.12Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007)
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown."8.31Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."7.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
" Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment."7.81Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015)
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches."7.77Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases."7.76Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010)
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis."7.75Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009)
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."7.74Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003."7.74[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007)
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration."7.74Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007)
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches."7.73Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005)
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited."6.87Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018)
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy."6.80Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015)
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)."6.77Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012)
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."6.73Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007)
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis."5.33[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006)
"Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy."5.32Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004)
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor."5.31Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002)
"The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)."5.17Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013)
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches."5.12Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007)
"Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)."5.09Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999)
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown."4.31Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023)
" Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment."3.81Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."3.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches."3.77Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP)."3.76[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi]. ( Doki, Y; Eguchi, H; Hashimoto, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H, 2010)
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases."3.76Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010)
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis."3.75Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009)
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003."3.74[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007)
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration."3.74Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007)
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."3.74Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches."3.73Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005)
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited."2.87Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018)
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy."2.80Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015)
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)."2.77Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012)
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."2.73Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007)
"Unresectable biliary tract cancers have a very poor prognosis."2.71Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study. ( Cantore, M; Carlone, N; Caudana, R; Fiorentini, G; Mambrini, A; Manni, A; Rabbi, C; Torri, T; Zamagni, D, 2003)
"The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor."2.70Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002)
"Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis."2.70[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis]. ( Ahn, SH; Cheong, JY; Chon, CY; Han, KH; Kim, JS; Lee, DY; Moon, YM; Seong, JS; Youn, YH, 2002)
"IORT using the INTRABEAM radiation system combined with portal vein infusion chemotherapy is promising for select patients with PVTT."1.56INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. ( Han, M; He, Y; Liang, H; Shao, Z; Song, X, 2020)
" In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy)."1.46Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. ( Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Seong, J; Song, JE; Song, K; Won, JY, 2017)
"Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%."1.43Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. ( Choi, GH; Choi, JS; Han, DH; Han, KH; Joo, DJ; Kim, MS; Kim, SI; Park, YN; Seong, J, 2016)
"Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port."1.39Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013)
"Capecitabine was given concomitantly at a dose of 600 mg/m2 twice daily during radiotherapy."1.39Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ, 2013)
"Metronomic chemotherapy may be a safe and useful palliative treatment in HCC patients with major PVT."1.38Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. ( Bae, SH; Cha, JH; Choi, BG; Choi, JY; Chun, HJ; Jang, JW; Kim, HL; Woo, HY; Yoon, SK; Youn, JM, 2012)
"The prognosis for hepatocellular carcinoma (HCC) along with portal vein tumor thrombi (PVTT) is poor, and surgery has not been considered an option."1.38Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. ( Liu, B; Liu, J; Ou, Q; Wang, Y; Zhang, D, 2012)
"We performed an operation for cancer of the rectum."1.36[Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer]. ( Hosokawa, T; Iwao, Y; Koshiishi, H; Koshinaga, T; Matsuyama, T; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H, 2010)
"These patients can also be affected by superior vena cava syndrome causing dyspnea followed by trunk or extremity swelling."1.35Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation. ( Kickuth, R; Sauter, A; Schmidt, F; Triller, J, 2008)
"The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)."1.33Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005)
"Colorectal cancer patients with central venous catheters (CVC) for pharmacokinetic modulating chemotherapy (PMC) have a substantial risk of venous thromboembolism (VTE)."1.33Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. ( Fujiwara, Y; Gega, M; Hashimoto-Tamaoki, T; Higasa, S; Ikeuchi, H; Inoue, T; Nakano, H; Noda, M; Oshima, T; Sakaki, T; Shoji, Y; Tsukamoto, K; Yamamura, T; Yanagi, H; Yoshikawa, R, 2005)
"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombosis of the main trunk or major branches of the portal vein (mPVTT) is extremely poor, even if it is curatively resected."1.33Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. ( Mimura, T; Niguma, T; Tutui, N, 2005)
"To estimate the risk of venous thrombosis associated with pancreatic malignancies we followed a cohort of patients with pancreatic cancer (n = 202)."1.33High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. ( Blom, JW; Osanto, S; Rosendaal, FR, 2006)
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis."1.33[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006)
"Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy."1.32Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004)
"Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis, and the development of new therapeutic strategies is necessary."1.31Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. ( Kaneko, S; Kobayashi, K; Urabe, T, 2002)
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor."1.31Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002)

Research

Studies (63)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (3.17)18.2507
2000's29 (46.03)29.6817
2010's28 (44.44)24.3611
2020's4 (6.35)2.80

Authors

AuthorsStudies
Narita, H1
Kawaratani, H1
Shibamoto, A1
Takeda, S1
Ozutsumi, T1
Tsuji, Y1
Fujinaga, Y1
Kitagawa, K1
Nishimura, N1
Hokuto, D1
Sho, M1
Yoshiji, H1
Fu, Y1
Peng, W1
Zhang, W1
Yang, Z1
Hu, Z1
Pang, Y1
Hu, D1
Chen, J1
Wang, J1
Zhou, Z1
Xu, L1
Chen, M1
Zhang, Y1
Ding, Y1
Wang, S1
Qiu, Z1
Zhu, C1
Wang, Y2
Zhao, S1
Qiu, W1
Wang, K1
Lv, J1
Qi, W1
Nakamura, M3
Ishigure, K1
Watanabe, T1
Mashita, N1
Tobinaga, J1
Fukuyama, R1
Song, X1
He, Y1
Liang, H1
Han, M1
Shao, Z1
Song, JE1
Jung, KS1
Kim, DY3
Song, K1
Won, JY1
Lee, HW1
Kim, BK1
Kim, SU3
Park, JY4
Ahn, SH3
Seong, J3
Han, KH4
Greally, M1
Pilson, K1
Linehan, A1
O'Keane, C1
Shields, CJ1
Conneely, JB1
McCaffrey, JA1
Choi, JH1
Chung, WJ2
Bae, SH5
Song, DS3
Song, MJ3
Kim, YS2
Yim, HJ2
Jung, YK1
Suh, SJ1
Cho, SB2
Khanna, A1
Reece-Smith, AM1
Cunnell, M1
Madhusudan, S1
Thomas, A1
Bowrey, DJ1
Parsons, SL1
Furuyama, H1
Fuji, H1
Okumura, S1
Nishigori, T1
Kadokawa, Y1
Kondo, M3
Machimoto, T1
Asao, Y1
Yoshimura, T1
Lee, SW1
Kim, HY1
Lee, YJ2
Oh, JS1
Chun, HJ3
Lee, HG1
Choi, JY3
Yoon, SK3
Olgun, DC1
Bakan, S1
Samanci, C1
Tutar, O1
Demiryas, S1
Korkmazer, B1
Kantarci, F1
Muñoz Martín, AJ1
García Alfonso, P1
Rupérez Blanco, AB1
Pérez Ramírez, S1
Blanco Codesido, M1
Martín Jiménez, M1
Jang, JY1
Lee, SH1
Park, SY1
Yang, JM1
Wu, J1
Huang, WJ1
Wang, HY1
Wang, YF1
Peng, BG2
Zhou, Q2
Al-Hameed, FM1
Nagamatsu, H2
Sumie, S3
Niizeki, T1
Tajiri, N1
Iwamoto, H2
Aino, H1
Nakano, M1
Shimose, S1
Satani, M1
Okamura, S1
Kuromatsu, R2
Matsugaki, S1
Kurogi, J1
Kajiwara, M1
Koga, H1
Torimura, T2
Han, DH1
Joo, DJ1
Kim, MS2
Choi, GH1
Choi, JS1
Park, YN1
Kim, SI1
Redana, S1
Sharp, A1
Lote, H1
Mohammed, K1
Papadimitraki, E1
Capelan, M1
Ring, A1
Akiyama, M1
Miyaaki, H1
Miuma, S1
Shibata, H1
Fujimoto, M1
Takeshita, S1
Ozawa, E1
Ichikawa, T1
Nakao, K1
Eguchi, K1
Fernández Sarabia, MT1
Rodríguez García, JM1
Cardenal Escarcena, A1
Serrano Vicente, J1
García Bernardo, L1
Sun, B1
Luo, M1
Lu, Z1
Meng, Y1
Wu, S1
Wu, M1
Eun, JR1
Lee, HJ1
Moon, HJ1
Kim, TN1
Kim, JW1
Chang, JC1
Katamura, Y1
Aikata, H2
Kimura, Y1
Kawaoka, T2
Takaki, S2
Waki, K1
Hiramatsu, A1
Kawakami, Y1
Takahashi, S2
Ishikawa, M1
Hieda, M1
Kakizawa, H1
Chayama, K2
Hirooka, M1
Koizumi, Y1
Kisaka, Y1
Abe, M1
Murakami, H1
Matsuura, B1
Hiasa, Y1
Onji, M1
Hiraki, M1
Mizukami, N1
Yoshida, H1
Sata, M2
Hosokawa, T1
Tokita, H1
Matsuyama, T1
Sakamoto, K1
Nishida, K1
Iwao, Y1
Koshiishi, H1
Okamura, T1
Koshinaga, T1
Hashimoto, Y1
Wada, H5
Kobayashi, S2
Marubashi, S4
Eguchi, H3
Takeda, Y2
Tanemura, M2
Umeshita, K6
Doki, Y2
Mori, M2
Nagano, H6
Tomimaru, Y1
Osuga, K1
Kasai, K1
Ushio, A1
Kasai, Y1
Sawara, K1
Miyamoto, Y1
Oikawa, K1
Kuroda, H1
Takikawa, Y1
Suzuki, K1
Liu, J1
Zhang, D1
Liu, B1
Ou, Q1
Woo, HY1
Youn, JM1
Jang, JW3
Cha, JH1
Kim, HL1
Choi, BG2
Park, MS1
Chon, CY2
Kim, JY1
Yoo, EJ1
Kwon, JH1
Kim, KJ1
Kay, CS1
Ducreux, M1
Adenis, A1
Pignon, JP1
François, E1
Chauffert, B1
Ichanté, JL1
Boucher, E1
Ychou, M1
Pierga, JY1
Montoto-Grillot, C1
Conroy, T1
Ando, E1
Tanaka, M1
Yamashita, F1
Yutani, S1
Fukumori, K1
Yano, Y1
Okuda, K1
Mainwaring, CJ1
Naylor, E1
Jerwood, S1
Hall, V1
Page, A1
James, CM1
Kim, JS2
Lee, DY1
Seong, JS1
Youn, YH1
Cheong, JY2
Moon, YM1
Videtic, GM1
Campbell, C1
Vincent, MD1
Lai, YC1
Shih, CY1
Jeng, CM1
Yang, SS1
Hu, JT1
Sung, YC1
Liu, HT1
Hou, SM1
Wu, CH1
Chen, TK1
Tham, J1
Albertsson, M1
Cantore, M2
Mambrini, A2
Fiorentini, G2
Rabbi, C2
Zamagni, D2
Caudana, R2
Pennucci, C1
Sanguinetti, F1
Lombardi, M1
Nicoli, N1
Yoshikawa, R1
Yanagi, H1
Noda, M1
Ikeuchi, H1
Nakano, H1
Gega, M1
Tsukamoto, K1
Oshima, T1
Inoue, T1
Fujiwara, Y1
Shoji, Y1
Sakaki, T1
Higasa, S1
Hashimoto-Tamaoki, T1
Yamamura, T1
Niguma, T1
Mimura, T1
Tutui, N1
Ota, H3
Sakon, M4
Yamamoto, T2
Damdinsuren, B2
Miyamoto, A2
Dono, K4
Nakamori, S3
Wakasa, K2
Monden, M4
Blom, JW1
Osanto, S1
Rosendaal, FR1
Lim, TY1
Cho, SW1
Sim, SJ1
Choi, SJ1
Choi, JW1
Kwon, HC1
Lee, KM1
Kim, JK1
Won, JH1
Yoo, BM1
Lee, KJ1
Hahm, KB1
Kim, JH1
Oh, HJ1
Lee, SY1
Kim, CW1
Chang, UI1
Nam, SW1
Cha, SB1
Byun, JY1
Carlone, N1
Manni, A1
Torri, T1
Donadon, M1
Vauthey, JN1
Loyer, EM1
Charnsangavej, C1
Abdalla, EK1
Imai, Y2
Fukuda, K1
Matsumoto, H1
Noda, T1
Naganuma, A1
Toyoda, M1
Hamada, T1
Hagiwara, S1
Yanagisawa, M1
Kosone, T1
Arai, H1
Abe, T1
Takagi, H1
Sauter, A1
Triller, J1
Schmidt, F1
Kickuth, R1
Ishikawa, T1
Imai, M1
Kamimura, H1
Tsuchiya, A1
Togashi, T1
Watanabe, K1
Seki, K1
Ohta, H1
Yoshida, T1
Kamimura, T1
Uka, K1
Miki, D1
Jeong, SC1
Toyota, N1
Ito, K1
Liang, LJ1
Hu, WJ1
Yin, XY1
Li, DM1
Lu, MD1
Martenson, JA1
Shanahan, TG1
O'Connell, MJ1
Cobau, CD1
Schroeder, G1
Burch, PA1
Levitt, R1
Rowland, KM1
Orlando, L1
Colleoni, M1
Nolè, F1
Biffi, R1
Rocca, A1
Curigliano, G1
Ferretti, G1
Peruzzotti, G1
de Braud, F1
Masci, G1
Goldhirsch, A1
Schaefer, U1
Micke, O1
Schueller, P1
Willich, N1
Meropol, NJ1
Rustum, YM1
Creaven, PJ1
Blumenson, LE1
Frank, C1
Kaneko, S1
Urabe, T1
Kobayashi, K1
Yamada, A1
Kawata, S1
Iijima, S1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949]Phase 1/Phase 239 participants (Anticipated)Interventional2019-12-01Not yet recruiting
Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587]Early Phase 160 participants (Anticipated)Interventional2021-07-01Enrolling by invitation
International Registry on Cholangiocarcinoma Treatment[NCT01920503]40 participants (Anticipated)Observational [Patient Registry]2013-07-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for fluorouracil and Deep Vein Thrombosis

ArticleYear
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Carcinoma, Hepatocellular; Cell Death; Cisplatin; Fluorouracil; Humans; Immunotherapy; Liver Neoplas

2023

Trials

16 trials available for fluorouracil and Deep Vein Thrombosis

ArticleYear
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cat

2018
Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo

2015
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cispl

2016
Clinical studies of laser ablation in treatment of primary liver carcinoma-associated portal vein tumor thrombus.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod

2010
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Cancer, 2012, Jul-01, Volume: 118, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2012
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined

2013
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2013
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
    Cancer, 2002, Aug-01, Volume: 95, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2002
[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis].
    Taehan Kan Hakhoe chi = The Korean journal of hepatology, 2002, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Fluo

2002
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    World journal of gastroenterology, 2003, Volume: 9, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Fluoro

2003
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

2007
Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
    Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary

2003
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
    World journal of gastroenterology, 2007, Nov-07, Volume: 13, Issue:41

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc

2007
Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
    Cancer, 2007, Dec-01, Volume: 110, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod

2007
Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy.
    Cancer, 1999, Aug-15, Volume: 86, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Modality

1999
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Cancer investigation, 1999, Volume: 17, Issue:1

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr

1999

Other Studies

46 other studies available for fluorouracil and Deep Vein Thrombosis

ArticleYear
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
    Clinical journal of gastroenterology, 2022, Volume: 15, Issue:5

    Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Port

2022
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Journal of gastroenterology, 2023, Volume: 58, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Ind

2023
[A Case of FOLFOXIRI plus BV Therapy Responding to Liver Metastasis of Rectal Cancer with the Portal Venous Tumor Thrombi(Vp4)as Oncologic Emergency].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatectom

2019
INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus.
    BMC surgery, 2020, Aug-01, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T

2020
Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    International journal of radiation oncology, biology, physics, 2017, 10-01, Volume: 99, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellu

2017
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein.
    Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:3

    Topics: Adenocarcinoma, Mucinous; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothec

2019
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2014
[A case of recurrent colon cancer developed thrombosis in superior mesenteric vein after chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo

2013
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
    World journal of gastroenterology, 2013, Aug-07, Volume: 19, Issue:29

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chi-Square D

2013
Simultaneous thrombosis of superior mesenteric artery and superior mesenteric vein following chemotherapy: MDCT findings.
    Japanese journal of radiology, 2014, Volume: 32, Issue:2

    Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil;

2014
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014, Volume: 16, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati

2014
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer.
    Saudi medical journal, 2015, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast;

2015
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
    Yonsei medical journal, 2016, Volume: 57, Issue:5

    Topics: Adult; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluor

2016
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
    Breast (Edinburgh, Scotland), 2016, Volume: 30

    Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas

2016
Significance of trans-hepatic arterial chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
    Oncology reports, 2008, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2008
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:11

    Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agen

2008
Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Scandinavian journal of gastroenterology, 2009, Volume: 44, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2009
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2010
Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Combin

2010
Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis.
    Alimentary pharmacology & therapeutics, 2010, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cause of Death; Cis

2010
[Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antin

2010
[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2010
Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci

2011
Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit Analy

2012
Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
    The Korean journal of hepatology, 2012, Volume: 18, Issue:1

    Topics: Administration, Metronomic; Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepat

2012
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Radiation oncology (London, England), 2013, Jan-16, Volume: 8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiothe

2013
Superior venocaval obstruction secondary to central venous catheter-related thromboses in two patients with metastatic colorectal carcinoma receiving weekly 5-flurouracil. Should adjusted-dose warfarin be used as thromboprophylaxis?
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Colorectal Neoplasms;

2002
Primary chemoradiation as definitive treatment for unresectable cancer of the trachea.
    Canadian respiratory journal, 2003, Volume: 10, Issue:3

    Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2003
Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review.
    Acta oncologica (Stockholm, Sweden), 2004, Volume: 43, Issue:1

    Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2004
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola

2005
Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy.
    Oncology reports, 2005, Volume: 13, Issue:4

    Topics: Adult; Aged; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Catheterization

2005
Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study.
    Journal of hepato-biliary-pancreatic surgery, 2005, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2005
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
    British journal of cancer, 2005, Sep-05, Volume: 93, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Prog

2005
High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cohort Studies; Female; Fibrinolytic Agents; Fluorouracil; Humans;

2006
[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
    The Korean journal of hepatology, 2006, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2006
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
    World journal of gastroenterology, 2006, Oct-28, Volume: 12, Issue:40

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2006
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.
    International journal of clinical oncology, 2007, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Hepatectomy

2007
[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2007
Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation.
    Cardiovascular and interventional radiology, 2008, Volume: 31 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization, Peripheral; Colorectal Neoplasms; C

2008
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
    Journal of gastroenterology, 2007, Volume: 42, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cohort Studi

2007
Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.
    World journal of surgery, 2008, Volume: 32, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju

2008
Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea

2000
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
    Radiology, 2000, Volume: 216, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2000
Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis.
    Oncology, 2002, Volume: 62 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2002
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
    Cancer, 2002, Jan-15, Volume: 94, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo

2002